Grail (GRAL) Competitors $14.80 -1.01 (-6.39%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends GRAL vs. FTRE, VRDN, TDOC, AHCO, CDNA, PNTG, AVAH, CSTL, INNV, and AGLShould you be buying Grail stock or one of its competitors? The main competitors of Grail include Fortrea (FTRE), Viridian Therapeutics (VRDN), Teladoc Health (TDOC), AdaptHealth (AHCO), CareDx (CDNA), The Pennant Group (PNTG), Aveanna Healthcare (AVAH), Castle Biosciences (CSTL), InnovAge (INNV), and agilon health (AGL). These companies are all part of the "healthcare" industry. Grail vs. Fortrea Viridian Therapeutics Teladoc Health AdaptHealth CareDx The Pennant Group Aveanna Healthcare Castle Biosciences InnovAge agilon health Fortrea (NASDAQ:FTRE) and Grail (NASDAQ:GRAL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, community ranking, profitability, analyst recommendations, earnings and dividends. Is FTRE or GRAL more profitable? Grail has a net margin of 0.00% compared to Fortrea's net margin of -10.99%. Fortrea's return on equity of 2.00% beat Grail's return on equity.Company Net Margins Return on Equity Return on Assets Fortrea-10.99% 2.00% 0.80% Grail N/A N/A N/A Which has stronger earnings & valuation, FTRE or GRAL? Grail has lower revenue, but higher earnings than Fortrea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFortrea$3.11B0.56-$3.40M-$3.42-5.65GrailN/AN/AN/AN/AN/A Does the MarketBeat Community favor FTRE or GRAL? Fortrea received 11 more outperform votes than Grail when rated by MarketBeat users. Likewise, 27.50% of users gave Fortrea an outperform vote while only 0.00% of users gave Grail an outperform vote. CompanyUnderperformOutperformFortreaOutperform Votes1127.50% Underperform Votes2972.50% GrailOutperform VotesNo VotesUnderperform Votes2100.00% Do analysts rate FTRE or GRAL? Fortrea currently has a consensus target price of $24.50, indicating a potential upside of 26.68%. Given Fortrea's stronger consensus rating and higher probable upside, research analysts clearly believe Fortrea is more favorable than Grail.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortrea 1 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.25Grail 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to FTRE or GRAL? In the previous week, Fortrea had 4 more articles in the media than Grail. MarketBeat recorded 14 mentions for Fortrea and 10 mentions for Grail. Grail's average media sentiment score of 0.61 beat Fortrea's score of 0.49 indicating that Grail is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Grail 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryFortrea beats Grail on 10 of the 12 factors compared between the two stocks. Ad WealthPressThe Tesla Trade Is Back In BusinessIf you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Get Grail News Delivered to You Automatically Sign up to receive the latest news and ratings for GRAL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRAL vs. The Competition Export to ExcelMetricGrailMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$459.53M$2.84B$5.16B$8.74BDividend YieldN/A1.72%5.18%4.08%P/E RatioN/A9.2768.5613.82Price / SalesN/A211.141,271.8787.50Price / CashN/A373.0039.7135.24Price / Book0.182.996.485.93Net IncomeN/A-$32.88M$119.82M$225.73M7 Day Performance2.21%-5.71%-5.13%-1.34%1 Month Performance4.23%-4.39%-2.71%1.15%1 Year PerformanceN/A21.23%31.10%24.02% Grail Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRALGrail0.3659 of 5 stars$14.80-6.4%N/AN/A$459.53MN/A0.001,360Analyst ForecastShort Interest ↑News CoverageFTREFortrea3.3035 of 5 stars$18.97-6.1%N/A-40.4%$1.70B$3.11B-5.5518,000Earnings ReportVRDNViridian Therapeutics2.4396 of 5 stars$20.30-6.2%N/A+32.5%$1.61B$310,000.00-4.7150Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageTDOCTeladoc Health3.4866 of 5 stars$8.93-0.3%N/A-45.6%$1.54B$2.60B-1.555,600Analyst ForecastAnalyst RevisionNews CoverageGap UpAHCOAdaptHealth2.1523 of 5 stars$9.75-2.9%N/A+16.4%$1.31B$3.20B-5.9110,700Analyst ForecastCDNACareDx4.0677 of 5 stars$21.57+0.1%N/A+131.9%$1.16B$280.32M-7.99740PNTGThe Pennant Group3.4942 of 5 stars$31.91+0.0%N/A+146.7%$1.10B$544.89M46.935,791Short Interest ↑News CoverageAVAHAveanna Healthcare0.9619 of 5 stars$5.53+0.4%N/A+196.3%$1.07B$1.90B-16.2633,500Positive NewsCSTLCastle Biosciences3.581 of 5 stars$29.86-3.1%N/A+46.0%$836.38M$219.79M149.31540Short Interest ↓INNVInnovAge1.0183 of 5 stars$5.36+1.1%N/A-4.6%$726.07M$763.85M-44.672,350AGLagilon health2.3329 of 5 stars$1.69-1.5%N/A-86.7%$694.25M$4.32B-1.791,117Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies Fortrea Alternatives Viridian Therapeutics Alternatives Teladoc Health Alternatives AdaptHealth Alternatives CareDx Alternatives The Pennant Group Alternatives Aveanna Healthcare Alternatives Castle Biosciences Alternatives InnovAge Alternatives agilon health Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GRAL) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grail, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grail With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRAL Stock Alerts